Biologic drugs are produced by genetically-modified organisms such as bacteria or cells cultured in a laboratory.
Dupilumab is the first biologic treatment for atopic eczema. But what is its mechanism of action and does it really work?
Continue reading this article to get the right information about eczema treatment and recent studies about it simplified!
What is eczema?
Atopic dermatitis (eczema) is a condition that causes dry, itchy, and inflamed skin. It’s common in young children but can occur at any age. Atopic dermatitis is long-lasting (chronic) and tends to flare sometimes. It can be irritating but it’s not contagious.
What Is Dupilumab?
The human body uses chemical messengers called interleukins (ILs) to communicate and help fight off harmful viruses and bacteria. The immune system of people with inflammatory conditions like atopic eczema overreacts to allergens (e.g. dust, mold, pollen). This triggers the production of certain ILs, which cause greater inflammation. It is this chronic inflammation that leads to symptoms of eczema such as itchy, dry patches on the skin that are red or darker than a person’s normal skin color.
Biologics work by blocking ILs from binding to their cell receptors which stops the immune system from overreacting. Dupilumab works on two specific ILs thought to contribute to atopic conditions: IL-4 and IL-13. By blocking IL-4 and IL-13 from binding to their cell receptors, dupilumab limits the overreaction of the immune system, dampening down the chronic inflammatory response and lessening the symptoms of atopic eczema.
What has the research shown?
The first study to treat moderate-to-severe eczema in infants and children 6 months to 5 years old with a biologic drug rather than immune-suppressing medications shows that the drug was highly effective in reducing the signs and symptoms of eczema.
More than half of children had at least a 75% reduction in signs of eczema and itch.
About the Author: Dr. Donika Vata is a medical doctor from Ferizaj, Kosovo. She studied general medicine from University of Hasan Prishtina.
She has been writing about medical and skincare related issue in journals, social media websites, and books. She was working for some well reputed clinics such as Telehealth Pro- Online consultations, German Cancer Center, and AppLMD. Dr. Donika was also volunteering in the Covid-19 pandemic.
Currently, she is working as a medical doctor and researcher in a dermatology clinic.